The Myocarditis Foundation, And Donations From Financially Interested Parties

It’s a narrative seen all too often lately: heart problems and death among young and healthy people is common. There’s nothing too alarming. Well, is that really the case? Are things this straightforward, or is something obvious not being discussed?

On the surface, there’s nothing wrong with an organization whose purpose is to bring public awareness to common health problems. There are certainly many of them. The Myocarditis Foundation is just one of these groups.

Upon digging a little deeper, there are questions about this group, and what its interests really are. In particular, it’s curious where their financing comes from, and what they leave out of the conversation. But first, a bit of backstory:

Regeneron was one of the companies in 2020 who was vying to get a cure onto the market for this so-called “Covid-19”. They ultimately got Regen-CoV (casirivimab and imdevimab) emergency use authorization with the FDA. This obviously wasn’t full approval, but allowed the products to be distributed. Regen-CoV has some interesting side effects, to put it mildly.

The story gets more interesting. Regeneron has many products either in testing, or already on the market. One such case is a partnership with Sanofi on a cancer drug. Another drug was something called Arcalyst, which was to be repurposed by a company called Kiniksa Pharmaceuticals. This essentially amounts to taking a commerical drug, and finding an entirely new purpose for it.

In its information for investors, Kiniksa explains how this happened to come about. They are quite open that this is someone else’s creation.

Rilonacept was discovered and developed by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the FDA under the brand name ARCALYST® for the treatment of CAPS. Kiniksa licensed rilonacept from Regeneron in 2017 for evaluation in diseases believed to be mediated by both IL-1α and IL-1β, including recurrent pericarditis. The FDA granted Breakthrough Therapy designation to rilonacept for recurrent pericarditis in 2019. Based on the Phase 3 RHAPSODY data announced today, the Biologic License Application (BLA) for CAPS will transfer to Kiniksa, and the company plans to submit an sBLA with the FDA in recurrent pericarditis later this year. Upon receipt of FDA approval for rilonacept in recurrent pericarditis, Kiniksa would assume the sales and distribution of rilonacept for the approved indications in the United States and will evenly split profits on sales with Regeneron.

Kiniksa Pharmaceuticals was founded in 2015 in Bermuda. Despite being a “new” company, there were able to raise $80 million relatively quickly. Over the next year, they would obtain the exclusive rights to rilonacept. 2018, they were able to raise $170.7 million with their IPO, or initial public offering. 2019, the FDA conferred “Breakthrough Therapy” designation on them and they went into Stage 2 testing. All of this is pretty impressive for a company that seemingly came out of nowhere.

June 29, 2020 Kiniksa announced the Phase 3 testing for its drug to combat recurring pericarditis. What a coincidence that they would soon have such a growing market for their product.

March 18, 2021, Kiniksa received FDA approval for its product. Proprietary name is Arcalyst, and the established name is Rilonacept. “Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older.” Interesting how this product came along just in time for the wave of heart problems that would ensue.

[1] Regeneron is involved in conducting research into various cures for Covid-19. Of course, so are many others.
[2] Kiniksa takes an existing product from Regeneron. It’s used as a cure for pericarditis, the scale of which is likely made much worse by Covid-19 vaccines.

Problem. Reaction. Solution.

Now, what does all of this have to do with the Myocarditis Foundation? It turns out that Kiniksa Pharmaceuticals is one of their major donors. In their Spring 2021 newsletter, the Foundation celebrates the revelation of Kiniksa’s approval for recurring pericarditis with the FDA.

It’s curious that the other corporate donors are insurance companies. Just a thought, but perhaps there is some larger effort to limit liability of businesses everywhere.

A cynic may wonder if the Myocarditis Foundation’s focus on heart damage from Covid-19 is a way to boost business for Kiniksa, and to deflect attention from the long term effects of these vaccines. With so much money at stake, it’s hard to write off any possibility.

Looking through the tweets and publications of the Myocarditis Foundation, they never seem to address the elephant in the room: how many recent cases of heart problems are caused by these vaccines?

(1) https://twitter.com/myocarditisfndn/status/1461721312087486470
(2) https://www.regeneron.com/covid19
(3) Regeneron’s COVID-19 Response Efforts
(4) https://www.regencov.com/
(5) https://www.pharmalive.com/regeneron-and-sanofi-collaboration-receives-third-fda-drug-approval/
(6) https://www.kiniksa.com/about
(7) https://www.kiniksa.com/diseases
(8) https://investors.kiniksa.com/news-releases/news-release-details/kiniksa-announces-positive-data-phase-3-trial-rilonacept/
(9) Kiniksa Announces Positive Data from Phase 3 Trial of Rilonacept in Recurrent
(10) https://www.fda.gov/media/97001/download
(11) Corrected 20210930_ ANNUAL_Breakthrough_Approvals
(12) https://www.myocarditisfoundation.org/
(13) https://twitter.com/myocarditisfndn
(14) https://www.myocarditisfoundation.org/supporters/corporate-donors/
(15) Corporate Charitable Giving – Myocarditis Foundation
(16) https://www.myocarditisfoundation.org/wp-content/uploads/2021/01/2020-Financial-Summary.pdf
(17) https://www.myocarditisfoundation.org/newsletter/
(18) https://www.myocarditisfoundation.org/wp-content/uploads/2021/04/Spring-21-Newsletter.pdf
(19) Myocarditis Foundation Spring-21-Newsletter
(20) https://www.myocarditisfoundation.org/research-and-grants/research-and-grant-program/
(21) https://www.iscmf.org/
(22) https://www.iscmf.org/covidregistry

AND FOR SOME EXTRA READING:
(A) Canadian Pharmaceutical Sciences Foundation Funded By Big Pharma
(B) Canadian Pharmacists Association: Subsidies While They Lobby Against You
(C) CDN Immunization Research Network Funded By Pfizer, GSK, Sanofi
(D) B.C. Pharmacy Association Funded By Drug Companies
(E) U.S. Council On Patient Safety: Women’s Health
(F) Emergent BioSolutions Lobbying All Federal Parties
(G) British Fertility Society Funded By Pharmaceutical Companies
(H) American College Health Foundation Is Funded By Big Pharma-and-insurance/

3 Replies to “The Myocarditis Foundation, And Donations From Financially Interested Parties”

  1. Always, always, first they create the drug, then the disease. The most obvious case was that of non-existent bi-polar in children. The pharmacueitical had a drug called Ritalin, they created a hype around bi-polar in children, complete with shill doctors claiming an epidemic of bi-polar in children existed.

    Suddenly childhood became a disease and Ritalin became a best-seller.

    And of course, many parents raced their kids to the Ritalin pushers.